Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.67 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10694438 | 1.00 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10691896 | 1.00 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10691842 | 1.00 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10687830 | 1.00 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10693120 | 1.00 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10687786 | 1.00 | CYSLTR2 (0.67) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| Tomelukast SCHEMBL3944 | 0.99 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL10693436 | 0.96 | CYSLTR2 (0.63) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL9777248 | 0.90 | CYSLTR2 (0.57) | CYSLTR2CYSLTR1LMNAMEN1GLA | |
| SCHEMBL9643112 | 0.89 | CYSLTR2 (0.54) | CYSLTR2CYSLTR1LMNAMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0108592-B1 | LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1987-09-30 | — | — | EP | claimed |
| US-4661505-A | 4-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY) ALKANOIC ACIDS, TETRAZOLES, AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-04-28 | — | — | US | claimed |
| EP-0108592-A1 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1984-05-16 | — | — | EP | claimed |
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | DARA BIOSCIENCES, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1180686-B1 | REMEDIES FOR KIDNEY DISEASES AND METHOD FOR SCREENING THE SAME | CMIC CO LTD (JP) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009002433-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | DARA BIOSCIENCES, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20060120971-A1 | Agents and methods for administration to the central nervous system | SIGNUM PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006041922-A2 | AGENTS AND METHODS FOR ADMINISTRATION TO THE CENTRAL NERVOUS SYSTEM | DARA BIOSCIENCES, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| US-20040185503-A1 | Administering peroxisome proliferator-activated receptor agonist; assaying substance for up-regulating the expression of fatty acid-binding protein; glomerulonephritis, nephrotic syndrome, focal glomerulosclerosis | TANABE SEIYAKU CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6794154-B1 | COMPRISES ASSAYING A TEST SUBSTANCE FOR THE ACTIVITY OF UP-REGULATING THE EXPRESSION OF LIVER-TYPE FATTY ACID-BINDING PROTEIN (L-FABP) IN ANIMAL CELLS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS; | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-21 | — | — | US | disclosed |
| EP-1180686-A1 | REMEDIES FOR KIDNEY DISEASES AND METHOD FOR SCREENING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| US-4769482-A | Cyano and thiocyano intermediates | ELI LILLY AND COMPANY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0108592-B1 | LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1987-09-30 | — | — | EP | disclosed |
| US-4661505-A | 4-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY) ALKANOIC ACIDS, TETRAZOLES, AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0108592-A1 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210695-A1 | COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS | CPT1B, CPT1A, CPT2 | CYSLTR2 1860/4885CYSLTR1 1074/4885LMNA 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.